Objective: This systematic review and meta-analysis was undertaken to integrate previous findings and summarize the effect size of the association of interleukin-6 (IL-6) genetic polymorphism –174G/C with susceptibility to prostate cancer (PCa). Methods: All eligible studies of IL-6 –174G/C polymorphism and PCa risk were collected from the following electronic databases: PubMed and the Cochrane Library, with the last report up to June 1, 2011. Statistical analyses were performed by Review Manage version 5.0 and Stata 10.0. Results: A total of 7 independent studies, including 9,959 cases and 12,361 controls, were identified. When all studies were pooled, we did not detect a significant association of –174G/C polymorphism with PCa risk. When stratifying for race, similar results were obtained; evidence of a significant relation was absent in both Caucasians and the mixed population. After stratifying the studies by study types, –174G/C polymorphism was significantly associated with PCa risk when examining the contrast of CC + GC versus GG (OR = 1.44, 95% CI = 1.05–1.98, p = 0.03) in cohort studies but not in case-control studies. Conclusions: Our review suggest that –174G/C polymorphism is associated with an increased PCa risk in two cohort studies from one article. Additional well-designed studies are warranted to validate these findings.

Keywords:
Interleukin-6, Genetic polymorphism, Prostatic neoplasm, Meta-analysis, Association
1.
Jemal A, Siegel R, Xu J, et al: Cancer statistics, 2010. CA Cancer J Clin 2010;60:277–300.
2.
Jemal A, Ward E, Brawley O, et al: Cancer statistics, 2011. CA Cancer J Clin 2011;61:212–236.
3.
Shacter E, Weitzman SA: Chronic inflammation and cancer. Oncology 2002;16:217–226.
4.
Mosser DM, Zhang X: Interleukin-10: new perspectives on an old cytokine. Immunol Rev 2008;226:205–218.
5.
Serefoglou Z, Yapijakis C, Nkenke E, et al: Genetic association of cytokine DNA polymorphisms with head and neck cancer. Oral Oncol 2008;44:1093–1099.
6.
Howell WM, Rose-Zerilli MJ: Cytokine gene polymorphisms, cancer susceptibility, and prognosis. J Nutr 2007;137:194–199.
7.
Ogata A, Chauhan D, Teoh G, et al: IL-6 triggers cell growth via the Ras-dependent mitogen-activated protein kinase cascade. J Immunol 1997;159:2212–2221.
8.
Hirano T: Interleukin 6 and its receptor: ten years later. Int Rev Immunol 1998;16:249–284.
9.
Yu KD, Di GH, Fan L, et al: Lack of an association between a functional polymorphism in the interleukin-6 gene promoter and breast cancer risk: a meta-analysis involving 25,703 subjects. Breast Cancer Res Treat 2010;122:483–488.
10.
Wu D, Zou YF, Xu XY, et al: The association of genetic polymorphisms with cerebral palsy: a meta-analysis. Dev Med Child Neurol 2011;53:217–225.
11.
Valdes AM, Arden NK, Tamm A, et al: A meta-analysis of interleukin-6 promoter polymorphisms on risk of hip and knee osteoarthritis. Osteoarthritis Cartilage 2010;18:699–704.
12.
Zhang J, Dhakal IB, Lang NP, et al: Polymorphisms in inflammatory genes, plasma antioxidants, and prostate cancer risk. Cancer Causes Control 2010;21:1437–1444.
13.
Dossus L, Kaaks R, Canzian F, et al: PTGS2 and IL6 genetic variation and risk of breast and prostate cancer: results from the Breast and Prostate Cancer Cohort Consortium (BPC3). Carcinogenesis 2010;31:455–461.
14.
Moore SC, Leitzmann MF, Albanes D, et al: Adipokine genes and prostate cancer risk. Int J Cancer 2009;124:869–876.
15.
Pierce BL, Biggs ML, DeCambre M, et al: C-reactive protein, interleukin-6, and prostate cancer risk in men aged 65 years and older. Cancer Causes Control 2009;20:1193–1203.
16.
Kesarwani P, Ahirwar DK, Mandhani A, et al: Association between –174G/C promoter polymorphism of the interleukin-6 gene and progression of prostate cancer in North Indian population. DNA Cell Biol 2008;27:505–510.
17.
Michaud DS, Daugherty SE, Berndt SI, et al: Genetic polymorphisms of interleukin-1B (IL-1B), IL-6, IL-8, and IL-10 and risk of prostate cancer. Cancer Res 2006;66:4525–4530.
18.
Mantel N, Haenszel W: Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959;22:719–748.
19.
DerSimonian R, Laird N: Meta-analysis in clinical trials. Control Clin Trials 1986;7:177–188.
© 2012 S. Karger AG, Basel
2012
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.